RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

 
• By Dexter Jie Yan
  
PatientRecruitment
RemeGen is pulling out all the stops to enroll patients in a global Phase III clincial trial in generalized myasthenia gravis. • Source: Shutterstock

More from Clinical Trials

More from Rare Diseases